Skip to content
Search

Latest Stories

Pharmacy closures: Dispensing doctors urge 'deserted' rural patients to seek GP service

Pharmacy closures: Dispensing doctors urge 'deserted' rural patients to seek GP service

Earlier, a report from the National Pharmacy Association warned that many rural areas are at risk of becoming 'pharmacy deserts' if the current rate of pharmacy closures continues

The Dispensing Doctors’ Association (DDA) is advising patients left deserted due to pharmacy closures in rural areas to consult their general practice about accessing the GP dispensing service.


This recommendation comes in response to concerns that England’s rural areas are increasingly becoming pharmacy ‘deserts’, posing challenges for residents to access essential medications and healthcare services.

DDA chairman Dr Richard West said: “The GP dispensing service is designed to ensure NHS medicine supply in areas where people have little or no access to a pharmacy service.

“People in rural areas who now live more than a mile from a pharmacy should speak to their GP about whether they can receive the NHS GP dispensing service."

A new analysis by the National Pharmacy Association (NPA) found that rural areas have been

A recent analysis by the National Pharmacy Association (NPA) has found that rural areas have been hit the hardest by a wave of pharmacy closures over the past two years.

Published on Tuesday, the report revealed that 17 of the 20 council areas with the lowest number of pharmacies per 100,000 people were in rural locations.

It also cautions that if the current rate of closures persists, many rural regions could face the risk of becoming “pharmacy deserts.”

The analysis also revealed that West Berkshire has the lowest pharmacies per 100,000 people in the country, with more than four times fewer pharmacies compared to Westminster, which has the highest pharmacy provision.

However, the DDA highlighted that the county is served by at least 12 dispensing GP practices, offering NHS medicine dispensing and other services to 44,100 patients – over a third of their total registered patients.

The NPA asserted that pharmacy closures in rural towns and villages may force people to travel greater distances for essential medication, and urged the government to reverse budget cuts.

NPA chief executive Paul Rees said: “These shocking statistics show how a growing number of areas are at risk of becoming pharmacy deserts, with people in rural towns and villages having to travel longer and longer distances to get hold of the medication they need.”

However, the DDA argued that dispensing patients can access medication from a dispensing GP without even having to leave the GP surgery.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less